Skip to content

Friday, April 19, 2024

Latest:

When medicine becomes political
Cancer-predisposition variants associated with adverse outcomes in rhabdomyosarcoma
Collaborating with the community for autism research
Virtual education programs train clinicians around the world
First step to untangle DNA: capture gyrase like a lasso ropes cattle

Home
Momentum
From The Labs
- About From the Labs
- Follow From The Labs on Twitter
Policywise
- About PolicyWise
- Follow @BCMEthics on Twitter
The Stitch
- About The Stitch
Progress Notes
bcm.edu

PI3K inhibitor

Targeting MAPK4 may offer a new therapeutic opportunity for TNBC

January 27, 2022 AKT, cancer therapy, MAPK4, PI3K, PI3K inhibitor, Research, triple-negative breast cancer

MAPK4 seems to be involved in promoting triple-negative breast cancer growth and its resistance to certain therapies.

From the Labs Image of the Month:

From the Labs: Human retinal organoid.

Healthy Habits: A DOC-umentary Series

Archives

Archives

Search

©1998 - 2023 Baylor College of Medicine®
One Baylor Plaza, Houston, Texas 77030
(713) 798-4951